MALACHITE-II: PHASE 3B TRIAL OF OMBITASVIR/PARITAPREVIR/R AND DASABUVIR plus RIBAVIRIN OR TELAPREVIR plus PEGINTERFERON/RIBAVIRIN IN PEGINTERFERON/RIBAVIRIN TREATMENT-EXPERIENCED ADULTS WITH HCV GENOTYPE 1

被引：6
|
作者：
Dore, G. [1 ,2 ]
Knysz, B. [3 ]
Luo, Y. [4 ]
Janczewska, E. [5 ]
Streinu-Cercel, A. [6 ,7 ]
Caruntu, F. A. [6 ]
Motoc, A. [8 ]
Mazur, W. [9 ]
Shaw, D. [10 ]
Tornai, I. [11 ]
Sasadeusz, J. [12 ]
Skoien, R. [13 ]
Sullivan, D. [4 ]
Liu, X. [4 ]
Podsadecki, T. [4 ]
机构：
[1] UNSW Australia, Kirby Inst, Sydney, NSW, Australia
[2] St Vincents Hosp, Sydney, NSW 2010, Australia
[3] Wroclaw Med Univ, Wroclaw, Poland
[4] AbbVie Inc, N Chicago, IL USA
[5] ID Clin, Myslowice, Poland
[6] Natl Inst Infect Dis Prof Dr Matei Bals, Bucharest, Romania
[7] Carol Davila Univ Med & Pharm, Bucharest, Romania
[8] Hosp Infect Dis Dr Victor Babes, Bucharest, Romania
[9] Med Univ Silesia, Clin Dept Infect Dis, Katowice, Poland
[10] Royal Adelaide Hosp, Adelaide, SA 5000, Australia
[11] Univ Debrecen, Dept Med, Div Gastroenterol, Debrecen, Hungary
[12] Royal Melbourne Hosp, Melbourne, Vic, Australia
[13] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia
来源：
JOURNAL OF HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
10.1016/S0168-8278(15)31049-7
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P0847
引用
收藏
页码：S656 / S657
页数：2
相关论文
共 50 条
  • [1] MALACHITE-II: Phase 3b Trial of Ombitasvir/Paritaprevir/R and Dasabuvir plus Ribavirin or Telaprevir plus Peginterferon/Ribavirin in Peginterferon/Ribavirin Treatment-Experienced Adults With HCV Genotype 1
    Dore, Gregory J.
    Knysz, Brygida
    Luo, Yan
    Janczewska, Ewa
    Streinu-Cercel, Adrian
    Caruntu, Florin A.
    Motoc, Adriana
    Mazur, Wlodzimierz
    Shaw, David R.
    Tornai, Istvan
    Sasadeusz, Joseph
    Skoien, Richard
    Sullivan, Danielle
    Liu, Xuan
    Podsadecki, Thomas
    GASTROENTEROLOGY, 2015, 148 (04) : S1084 - S1085
  • [2] MALACHITE-I: PHASE 3B TRIAL OF OMBITASVIR/PARITAPREVIR/R AND DASABUVIR plus /- RIBAVIRIN OR TELAPREVIR plus PEGINTERFERON/RIBAVIRIN IN TREATMENT-NAIVE ADULTS WITH HCV GENOTYPE 1
    Conway, B.
    Janczewska, E.
    Luo, Y.
    Curescu, M.
    Greenbloom, S.
    Streinu-Cercel, A.
    Caruntu, F. A.
    Ghesquiere, W.
    Knysz, B.
    Mazur, W.
    Fuster, F.
    Motoc, A.
    Soza, A.
    Arama, V.
    Dalgard, O.
    Sullivan, D.
    Liu, X.
    Podsadecki, T.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S653 - S654
  • [3] MALACHITE-I: Phase 3b Trial of Ombitasvir/Paritaprevir/R and Dasabuvir plus /- Ribavirin or Telaprevir plus Peginterferon/Ribavirin in Treatment-Naive Adults With HCV Genotype 1
    Conway, Brian
    Janczewska, Ewa
    Luo, Yan
    Curescu, Manuela
    Greenbloom, Susan
    Streinu-Cercel, Adrian
    Caruntu, Florin A.
    Ghesquiere, Wayne
    Knysz, Brygida
    Mazur, Wlodzimierz
    Fuster, Francisco
    Motoc, Adriana
    Soza, Alejandro
    Arama, Victoria
    Dalgard, Olav
    Sullivan, Danielle
    Liu, Xuan
    Podsadecki, Thomas
    GASTROENTEROLOGY, 2015, 148 (04) : S1001 - S1002
  • [4] Ombitasvir/Paritaprevir/r and Dasabuvir plus /- Ribavirin is Better Tolerated Than Telaprevir plus Peginterferon/Ribavirin With Less Frequent and Less Severe Anemia in the MALACHITE-I and MALACHITE-II Trials
    Conway, Brian
    Luo, Yan
    Arama, Victoria
    Ghesquiere, Wayne
    Sasadeusz, Joe
    Skoien, Richard
    Soza, Alejandro
    Inglot, Malgorzata
    Sullivan, Danielle
    Podsadecki, Thomas
    Dore, Gregory
    HEPATOLOGY, 2015, 62 : 782A - 783A
  • [5] Comparison of simeprevir plus peginterferon/ribavirin and telaprevir plus peginterferon/ribavirin for patients with HCV Genotype 1
    Nakajima, Tomoaki
    Kimura, Mutuumi
    Arakawa, Tomohiro
    Kuwata, Yasuaki
    Ozeki, Itaru
    Sato, Takahiro
    Ohmura, Takumi
    Hige, Shuhei
    Karino, Yoshiyasu
    Toyota, Joji
    HEPATOLOGY, 2013, 58 : 1140A - 1141A
  • [6] Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine
    Lalezari, Jacob
    Sullivan, J. Greg
    Varunok, Peter
    Galen, Edward
    Kowdley, Kris V.
    Rustgi, Vinod
    Aguilar, Humberto
    Felizarta, Franco
    McGovern, Barbara
    King, Martin
    Polepally, Akshanth R.
    Cohen, Daniel E.
    JOURNAL OF HEPATOLOGY, 2015, 63 (02) : 364 - 369
  • [7] Ombitasvir, paritaprevir, and ritonavir with peginterferon-α2a plus ribavirin in treatment-experienced patients with chronic hepatitis C virus genotype 1 infection
    Bernstein, David
    Tripathi, Rakesh
    Cohen, Daniel E.
    HEPATIC MEDICINE-EVIDENCE AND RESEARCH, 2019, 11 : 35 - 40
  • [8] Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection
    Dore, Gregory J.
    Lawitz, Eric
    Hezode, Christophe
    Shafran, Stephen D.
    Ramji, Alnoor
    Tatum, Harvey A.
    Taliani, Gloria
    Tran, Albert
    Brunetto, Maurizia R.
    Zaltron, Serena
    Strasser, Simone I.
    Weis, Nina
    Ghesquiere, Wayne
    Lee, Samuel S.
    Larrey, Dominique
    Pol, Stanislas
    Harley, Hugh
    George, Jacob
    Fung, Scott K.
    de Ledinghen, Victor
    Hagens, Peggy
    McPhee, Fiona
    Hernandez, Dennis
    Cohen, David
    Cooney, Elizabeth
    Noviello, Stephanie
    Hughes, Eric A.
    GASTROENTEROLOGY, 2015, 148 (02) : 355 - U147
  • [9] Ombitasvir/Paritaprevir/r and Dasabuvir with Ribavirin for HCV Genotype 1 Patients with Decompensated Cirrhosis
    Mantry, Parvez S.
    Hanson, John
    Trinh, Roger
    Ramji, Alnoor
    Fredrick, Linda
    Abunimeh, Manal
    Canizaro, Leticia
    Liu, Li
    Shulman, Nancy
    Gordon, Stuart C.
    HEPATOLOGY, 2015, 62 : 568A - 569A
  • [10] Characterization of resistant variants in treatment-experienced genotype-1 HCV patients receiving telaprevir/peginterferon/ribavirin in Phase II clinical trials
    Bartels, D. J.
    Sullivan, J. C.
    Zhang, E. Z.
    Tigges, A. M.
    Dorrian, J. L.
    Kwong, A. D.
    Kieffer, T. L.
    ANTIVIRAL THERAPY, 2010, 15 : A29 - A29
12345